PF-219,061

From WikiMD.org
Jump to navigation Jump to search

PF-219,061

PF-219,061 (pronunciation: P-F-two-one-nine-zero-six-one) is a pharmaceutical compound currently under investigation for its potential therapeutic applications.

Etymology

The name "PF-219,061" is a proprietary designation given by the pharmaceutical company Pfizer. The "PF" stands for Pfizer, while "219,061" is a unique identifier for this specific compound within the company's research and development pipeline.

Description

PF-219,061 is a novel small molecule compound. It is part of a class of drugs known as kinase inhibitors, which work by blocking the action of a specific type of enzyme known as a kinase. This can help to regulate cell growth and division, making kinase inhibitors potentially useful in the treatment of certain types of cancer and other diseases.

Related Terms

  • Pfizer: The pharmaceutical company responsible for the development of PF-219,061.
  • Kinase inhibitor: A type of drug that PF-219,061 belongs to.
  • Small molecule: A low molecular weight organic compound that is often used as a drug or drug candidate.
  • Cancer: A group of diseases characterized by the uncontrolled growth and spread of abnormal cells, which kinase inhibitors like PF-219,061 may be used to treat.

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski